Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas

Cancer Research

Volumn 73, Issue 2, 2013, Pages 496-501

  Jin, Genglin ^a   Reitman, Zachary J ^a   Duncan, Christopher G ^a   Spasojevic, Ivan ^a   Gooden, David M ^b   Rasheed, B Ahmed ^a   Yang, Rui ^a   Lopez, Giselle Y ^a   He, Yiping ^a   McLendon, Roger E ^a   Bigner, Darell D ^a   Yan, Hai ^a  

^a DUKE CANCER INSTITUTE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYGLUTARIC ACID; ARGININE; ISOCITRATE DEHYDROGENASE 1; MUTANT PROTEIN;

ADULT; ALLELE; ARTICLE; ASTROCYTOMA; CANCER GRADING; CANCER GROWTH; CELL LEVEL; COLORECTAL CANCER; CONTROLLED STUDY; GAIN OF FUNCTION MUTATION; GENE TARGETING; GLIOBLASTOMA; GLIOMA CELL; HETEROZYGOTE; HUMAN; HUMAN CELL; IDH1 GENE; MALE; POINT MUTATION; PRIORITY JOURNAL; WILD TYPE; WORLD HEALTH ORGANIZATION;

ASTROCYTOMA; BRAIN NEOPLASMS; CELL LINE, TUMOR; GENOTYPE; GLIOBLASTOMA; GLIOMA; GLUTARATES; HUMANS; ISOCITRATE DEHYDROGENASE; MUTATION;

EID: 84872537829     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-2852     Document Type: Article

References (20)

1. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008;321: 1807-12.
2. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009;360: 765-73.
3. Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009;361: 1058-66.
4. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009;462: 739-44.
5. Jin G, Reitman ZJ, Spasojevic I, Batinic-Haberle I, Yang J, Schmidt- Kittler O, et al. 2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations. PLoS One 2011;6:e16812.
6. Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010;18: 553-67.
7. Xu W, Yang H, Liu Y, Yang Y, Wang P, KimSH, et al. Oncometabolite 2- hydroxyglutarate is a competitive inhibitor of alpha-ketoglutaratedependent dioxygenases. Cancer Cell 2011;19: 17-30.
8. Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S, Abdel-Wahab O, et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 2012;483: 474-8.
9. Turcan S, Rohle D, Goenka A, Walsh LA, Fang F, Yilmaz E, et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 2012;483: 479-83.
10. Bralten LB, Kloosterhof NK, Balvers R, Sacchetti A, Lapre L, Lamfers M, et al. IDH1 R132H decreases proliferation of glioma cell lines in vitro and in vivo. Ann Neurol 2011;69: 455-63.
11. Pietrak B, Zhao H, Qi H, Quinn C, Gao E, Boyer JG, et al. A tale of two subunits: how the neomorphic R132H IDH1 mutation enhances production of alphaHG. Biochemistry 2011;50: 4804-12.
12. Matsunaga H, Futakuchi-Tsuchida A, Takahashi M, Ishikawa T, Tsuji M, Ando O. IDH1 and IDH2 have critical roles in 2-hydroxyglutarate production in D-2-hydroxyglutarate dehydrogenase depleted cells. Biochem Biophys Res Commun 2012;423: 553-6.
13. Koivunen P, Lee S, Duncan CG, Lopez G, Lu G, Ramkissoon S, et al. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature 2012;483: 484-8.
14. Jin G, Cook S, Cui B, Chen WC, Keir ST, Killela P, et al.HDMXregulates p53 activity and confers chemoresistance to 3-bis(2-chloroethyl)-1- nitrosourea. Neuro-Oncol 2010;12: 956-66.
15. Rago C, Vogelstein B, Bunz F. Genetic knockouts and knockins in human somatic cells. Nat Protocols 2007;2: 2734-46.
16. Reitman ZJ, Jin G, Karoly ED, Spasojevic I, Yang J, Kinzler KW, et al. Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome. Proc Natl Acad Sci U S A 2011; 108: 3270-5.
17. Kelly JJ, Blough MD, Stechishin OD, Chan JA, Beauchamp D, Perizzolo M, et al. Oligodendroglioma cell lines containing t(1;19)(q10;p10). Neuro Oncol 2010;12: 745-55.
18. Luchman HA, Stechishin OD, Dang NH, Blough MD, Chesnelong C, Kelly JJ, et al. An in vivo patient-derived model of endogenous IDH1-mutant glioma. Neuro Oncol 2012;14: 184-91.
19. Jiao Y, Killela PJ, Reitman ZJ, Rasheed AB, Heaphy CM, de Wilde RF, et al. Frequent ATRX, CIC, and FUBP1 mutations refine the classification of malignant gliomas. Oncotarget 2012;3: 709-22.
20. Verhaak RG, Hoadley KA, Purdom E,WangV, Qi Y, Wilkerson MD, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010;17: 98-110.